Definitions
Sorry, no definitions found. You may find more data at sequella.
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word Sequella.
Examples
-
NIH grants Sequella its first non-tuberculosis SBIR to develop translocase 1 inhibitor SQ641 for treatment of Non-Tubercular Mycobacteria (NTM)
WN.com - Articles related to Eggs serve as factory for H1N1 vaccine ingredients 2010
-
Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiot ...
THE MEDICAL NEWS 2010
-
NIH grants Sequella its first non-tuberculosis SBIR to develop translocase 1 inhibitor SQ641 for treatment of Non-Tubercular Mycobacteria (NTM)
WN.com - Articles related to Gene map of anti-malaria plant could save millions 2010
-
NIH grants Sequella its first non-tuberculosis SBIR to develop translocase 1 inhibitor SQ641 for treatment of Non-Tubercular Mycobacteria (NTM)
WN.com - Articles related to Millions at risk if AIDS focus fades, says expert 2010
-
NIH grants Sequella its first non-tuberculosis SBIR to develop translocase 1 inhibitor SQ641 for treatment of Non-Tubercular Mycobacteria (NTM)
WN.com - Articles related to Millions at risk if AIDS focus fades, says expert 2010
-
To learn more about Sequella or their presentations at BioSquare or the BioEurope Spring conference, visit www. sequella.com.
unknown title 2009
-
March 03, 2009 / PRNewswire / -- Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing products for infectious diseases of epidemic potential has announced that Alan Klein, Sequella Executive Vice President for Corporate Development, will participate in a Panel at the BioSquare 2009 Meeting at the Lyon Congress Center in Lyon, France.
unknown title 2009
-
Sequella is a clinical stage biopharmaceutical company focused on commercializing improved treatments for infectious diseases of epidemic potential.
unknown title 2009
-
Through focused execution, clear commercialization pathways, and strategic partnerships, Sequella intends to commercialize a broad product portfolio designed to treat global health threats with significant market opportunity.
unknown title 2009
-
Sequella will also present on March 17, 2009 at 5: 00 PM in Room Yellow 3, Level 1, of the Infectious Diseases section at BioEurope Spring 2009 at the Milano Convention Centre in Milan,
unknown title 2009
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.